

Consensus Controversy?

INVESTIGATOR PERSPECTIVES ON PRACTICAL ISSUES AND RESEARCH QUESTIONS IN NON-HODGKIN LYMPHOMA

CME INFORMATION

TARGET AUDIENCE

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

Taken together, it is estimated that approximately 85,420 new non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) cases were identified in the United States in the year 2013, and 23,600 individuals died from these diseases. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic cancers, with more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

These proceedings from a CME symposium during the 55th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of various forms of NHL. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for NHL.

LEARNING OBJECTIVES

- Appraise recent data on therapeutic advances and changing practice standards in NHL, including CLL, and integrate this information, when appropriate, into current clinical care.
- Develop an algorithm for the risk-stratified induction treatment of follicular lymphoma, diffuse large B-cell lymphoma and mantle-cell lymphoma.
- Compare and contrast completed and ongoing clinical trials evaluating novel investigational approaches for B-cell lymphomas and CLL, and use this information to prioritize

clinical trial opportunities or expanded access programs available to patients.

- Appreciate the recent FDA approval of obinutuzumab, and discern how this agent can be optimally integrated into clinical practice for patients with CLL.
- Customize the selection of systemic therapy for patients with progressive mantle-cell lymphoma, recognizing the recent addition of lenalidomide and ibrutinib as FDA-endorsed options for these patients.
- Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma, and ensure appropriate supportive care measures to minimize side effects.
- Recall new data with and assess ongoing trials of investigational agents demonstrating promising activity in NHL.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHNHL14/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved

through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Brad S Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Professor
University of Wisconsin School of Medicine and Public Health
Associate Director for Clinical Research
UW Carbone Cancer Center
Madison, Wisconsin

Advisory Committee: Celgene Corporation, Cephalon Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company, Roche Laboratories Inc; **Contracted Research:** Abbott Laboratories, Cephalon Inc, Genentech BioOncology.

Mitchell R Smith, MD, PhD

Director of Lymphoid Malignancies Program at
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Advisory Committee: Celgene Corporation, Cephalon Inc;
Speakers Bureau: Allos Therapeutics, Spectrum Pharmaceuticals Inc.

Steven M Horwitz, MD

Assistant Attending
Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York

Consulting Agreements: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Janssen Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics; **Contracted Research:** Allos Therapeutics, Celgene Corporation, Infinity Pharmaceuticals Inc, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc.

Michele E Ghielmini, MD, PhD

Honorary Professor of Medicine
University of Bern
Medical Director
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland

Advisory Committee: Celgene Corporation, GlaxoSmithKline; Consulting Agreement: Millennium: The Takeda Oncology Company; **Speakers Bureau:** Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc.

Laurie H Sehn, MD, MPH

Centre for Lymphoid Cancer
BC Cancer Agency and University of British Columbia
Vancouver, British Columbia, Canada

Consulting Agreements: Amgen Inc, Celgene Corporation, Cephalon Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Lundbeck Canada Inc, Roche Laboratories Inc; **Contracted Research:** Lundbeck Canada Inc, Roche Laboratories Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2014

Expiration date: March 2015

Brad Kahl, MD

Fisher RI et al. **Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.** *J Clin Oncol* 2006;24(30):4867-74.

Goy A et al. **Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study.** *J Clin Oncol* 2013;31(29):3688-95.

Goy A et al. **Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study.** *Ann Oncol* 2009;20(3):520-5.

Hess G et al. **Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.** *J Clin Oncol* 2009;27(23):3822-9.

Wang ML et al. **Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.** *N Engl J Med* 2013;369(6):507-16.

Wang M et al. **Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial.** *Lancet Oncol* 2012;13(7):716-23.

Mitchell R Smith, MD, PhD

Anderson DR et al. **Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.** *Biochem Soc Trans* 1997;25(2):705-8.

Brown JR et al. **Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): Results from the phase 1b Galton trial (GAO4779g).** *Proc ASH* 2013;[Abstract 523](#).

Byrd JC et al. **Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.** *N Engl J Med* 2013;369(1):32-42.

Cartron G et al. **Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL).** EHA 2011;[Abstract 101](#).

Certo M et al. **Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.** *Cancer Cell* 2006;9(5):351-65.

Chen L et al. **Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.** *Mol Cell* 2005;17(3):393-403.

Clynes RA et al. **Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.** *Nat Med* 2000;6(4):443-6.

Cragg MS. **CD20 antibodies: Doing the time warp.** *Blood* 2011;118(2):219-20.

Fischer K et al. **Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.** *J Clin Oncol* 2012;30(26):3209-16.

Goede V et al. **Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): Final stage 2 results of the CLL11 trial.** *Proc ASH* 2013;[Abstract 6](#).

Golay J et al. **Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.** *Blood* 2000;95(12):3900-8.

Hallek M et al. **Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial.** *Lancet* 2010;376(9747):1164-74.

Hillmen P et al. **Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.** *J Clin Oncol* 2007;25(35):5616-23.

Kim H et al. **Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies.** *Nat Cell Biol* 2006;8(12):1348-58.

Lannutti BJ et al. **CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.** *Blood* 2011;117(2):591-4.

Morschhauser F et al. **Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia.** *Proc ASH* 2009;[Abstract 884](#).

Reff ME et al. **Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.** *Blood* 1994;83(2):435-45.

Shan D et al. **Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.** *Cancer Immunol Immunother* 2000;48(12):673-83.

Silverman GJ, Weisman S. **Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy.** *Arthritis Rheum* 2003;48(6):1484-92.

Tse C et al. **ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor.** *Cancer Res* 2008;68(9):3421-8.

Willis SN et al. **Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.** *Science* 2007;315(5813):856-9.

Steven M Horwitz, MD

A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody campath-1H (alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas. [NCT00646854](#)

Campuzano-Zuluaga G et al. **Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: A retrospective study of 167 cases.** *Leuk Lymphoma* 2013;54(11):2405-11.

Coiffier B et al. **Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.** *J Clin Oncol* 2012;30(6):631-6.

Coiffier B et al. **Romidepsin induces durable responses in patients with peripheral T-cell lymphoma: GPI-06-0002 study update.** *Blood* 2012;[Abstract 3641](#).

ECHELON-2: A comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature T-cell lymphomas. [NCT01777152](#)

Fanale MA et al. **Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphomas.** *Proc ASH* 2012;[Abstract 60](#).

Friedberg J et al. **Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL).** *Proc ASH* 2011;[Abstract 95](#).

Gardner LJ et al. **CD30 expression in follicular lymphoma.** *Arch Pathol Lab Med* 2001;125(8):1036-41.

Hu et al. **CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study.** *Blood* 2013;121(14), 2715-24.

Jacobsen E. **A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: Interim results.** *Proc ASH* 2012;[Abstract 2746](#).

Horwitz S et al. **Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): Results from the pivotal BELIEF trial.** *Proc ICML* 2013;[Abstract 153](#).

Horwitz S et al. **Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase- δ,γ , in patients with relapsed/refractory lymphoma.** *Proc ASCO* 2013;[Abstract 8518](#).

Krathen M et al. **Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression.** *Proc ASH* 2012;[Abstract 797](#).

O'Connor OA et al. **Belinostat, a novel pan-histone deacetylase inhibitor in relapsed or refractory peripheral T-cell lymphoma: Results from the BELIEF trial.** *Proc ASCO* 2013;[Abstract 8507](#).

O'Connor OA et al. **Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study.** *J Clin Oncol* 2011;29(9):1182-9.

Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma. [NCT01796002](#)

Pro B et al. **Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study.** *J Clin Oncol* 2012;30(18):2190-6.

Sabattini E et al. **CD30 expression in peripheral T-cell lymphomas.** *Haematologica* 2013;98(8):e81-e82.

Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients. [NCT01420679](#)

Taylor CR, Levenson RM. **Quantification of immunohistochemistry — Issues concerning methods, utility and semiquantitative assessment II.** *Histopathology* 2006;49(4):411-24.

Went P et al. **Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score.** *J Clin Oncol* 2006;24(16):2472-9.

Michele E Ghilmini, MD, PhD

Ardeshtna KM et al. **An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with Stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis.** *Proc ASH* 2010;[Abstract 6](#).

Burke JM et al. **Differences in quality of life between bendamustine plus rituximab compared with standard first-line treatments in patients with previously untreated advanced indolent non-Hodgkin's lymphoma or mantle cell lymphoma.** *Proc ASH* 2012;[Abstract 155](#).

Chiappella A et al. **Rituximab-CHOP21 plus lenalidomide is effective and feasible in elderly untreated diffuse large B-cell lymphoma: Results of phase II REAL07 study of the Fondazione Italiana Linfomi (FIL).** *Proc ASH* 2012;[Abstract 903](#).

Flinn IW et al. **An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study.** *Proc ASH* 2012;[Abstract 902](#).

Ghilmini M et al. **Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.** *Blood* 2004;103(12):4416-23.

Kahl BS et al. **Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma.** *Proc ASH* 2011;[Abstract LBA-6](#).

Kotla V et al. **Mechanism of action of lenalidomide in hematological malignancies.** *J Hematol Oncol* 2009;2:36.

Kridel R et al. **Pathogenesis of follicular lymphoma.** *J Clin Invest* 2012;122(10):3424-31.

Nowakowski GS et al. **Combination of lenalidomide with R-CHOP is well tolerated and effective as initial therapy for aggressive B-cell lymphomas — A phase II study.** *Proc ASH* 2012;[Abstract 689](#).

Rummel MJ et al. **Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial.** *Lancet* 2013;381(9873):1203-10.

Laurie H Sehn, MD, MPH

Akyurek N et al. **Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.** *Cancer* 2012;118(17):4173-83.

Barrans S et al. **Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.** *J Clin Oncol* 2010;28(20):3360-5.

Cunningham D et al. **Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles.** *Lancet* 2013;381(9880):1817-26.

Green TM et al. **Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.** *J Clin Oncol* 2012;30(28):3460-7.

Habermann TM et al. **Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.** *J Clin Oncol* 2006;24(19):3121-7.

Hernandez-Ilizaliturri FJ et al. **Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in non-germinal center B-cell-like than in germinal center B-cell-like phenotype.** *Cancer* 2011;117(22):5058-66.

Hitz F et al. **Outcome of patients with chemotherapy refractory and early progressive diffuse large B cell lymphoma after R-CHOP treatment.** *Blood* 2010;[Abstract 1751](#).

Horn H et al. **MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.** *Blood* 2012;121(12):2253-63.

Hu S et al. **CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study.** *Blood* 2013;121(14):2715-24.

Jaeger U et al. **Rituximab maintenance treatment versus observation in patients with aggressive B-cell lymphoma: Results of the AGMT NHL13 trial.** *Proc ICML* 2013;[Abstract 119](#).

Johnson NA et al. **Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.** *J Clin Oncol* 2012;30(28):3452-9.

Kojima M et al. **MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: Multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.** *Leuk Lymphoma* 2013;54(10):2149-54.

Lenz H et al. **Stromal gene signatures in large-B-cell lymphomas.** *New Engl J Med* 2008;359(22):2313-23.

Meyer PN et al. **Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.** *J Clin Oncol* 2011;29(2):200-7.

Morrison VA et al. **Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update.** *Proc ASCO* 2007. No abstract available

Obermann EC et al. **Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment.** *J Clin Pathol* 2009;62(8):754-6.

Savage KJ et al. **MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.** *Blood* 2009;114(17):3533-7.

Shaffer AL et al. **Pathogenesis of human B cell lymphomas.** *Annu Rev Immunol* 2012;30:565-610.

Stiff PJ et al. **Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.** *N Engl J Med* 2013;369(18):1681-90.

Sun H et al. **Outcome of patients with double-hit lymphomas treated with CODOX-M/IVAC + R followed by hematopoietic stem cell transplantation in British Columbia.** *Proc ASH* 2013;[Abstract 1788](#).

Visco C et al. **Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study.** *Leukemia* 2012;26(9):2103-13.

Wright G et al. **A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.** *Proc Natl Acad Sci* 2003;100(17):9991-6.

Ziepert M et al. **Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.** *J Clin Oncol* 2010;28(14):2373-80.